|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
Norepinephrine reuptake inhibitor
|
|
gptkbp:affects
|
Improved attention
Improved impulse control
Reduced hyperactivity
|
|
gptkbp:approves
|
gptkb:2002
gptkb:FDA
gptkb:Depression
Weight loss
Anxiety disorders
|
|
gptkbp:brand
|
gptkb:Strattera
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:class
|
Selective norepinephrine reuptake inhibitors
|
|
gptkbp:clinical_trial
|
ADHD treatment studies
ADHD in adults
ADHD in children
|
|
gptkbp:composed_of
|
Chemical synthesis
|
|
gptkbp:contraindication
|
gptkb:Monoamine_oxidase_inhibitors
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:dosage_form
|
gptkb:beer
40 to 100 mg daily
|
|
gptkbp:excretion
|
Urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Atomoxetine
|
|
gptkbp:ingredients
|
gptkb:Atomoxetine_hydrochloride
C17 H21 N
|
|
gptkbp:interacts_with
|
CY P2 D6 inhibitors
CY P2 D6 inducers
|
|
gptkbp:invention
|
Patented
|
|
gptkbp:is_available_on
|
gptkb:beer
|
|
gptkbp:is_used_for
|
gptkb:Attention_Deficit_Hyperactivity_Disorder
|
|
gptkbp:lifespan
|
5 to 20 hours
|
|
gptkbp:manager
|
Oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
Liver
|
|
gptkbp:premiered_on
|
1 to 2 weeks
|
|
gptkbp:previous_name
|
gptkb:Atomoxetine
|
|
gptkbp:research_areas
|
gptkb:hospital
gptkb:psychologist
Clinical psychology
Neuroscience
Pharmacology
Neuropharmacology
ADHD treatment
|
|
gptkbp:side_effect
|
gptkb:Insomnia
gptkb:Nausea
Fatigue
Dry mouth
Decreased appetite
|
|
gptkbp:social_structure
|
Aromatic amine
|
|
gptkbp:traded_on
|
gptkb:Strattera
|
|
gptkbp:bfsParent
|
gptkb:Searle_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|